EDN1 and pulmonary arterial hypertension: As discussed previously, clinical trials for chronic lung disease have largely been undertaken to repurpose therapies that are efficacious in PAH by targeting one of the vasodilator pathways: prostacyclin, endothelin-1, and NO.